A Phase I, Multi-Center, Dose-Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of AV-412 Administered Orally Three Times Weekly to Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 30 Sep 2011
At a glance
- Drugs AV 412 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 20 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jul 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
- 20 May 2009 Planned number of patients changed from 40 to 40.